Seastar Medical anticipates NEUTRALIZE-AKI enrollment completion by midyear 2027 while preparing modular PMA submissions

Earnings Call Insights: SeaStar Medical Holding Corporation (ICU) Q3 2026

Management view

• "We saw strong QUELIMMUNE demand in the ultra-rare pediatric AKI market" and management emphasized new registry data, with CEO Eric Schlorff highlighting "the statistically significant higher survival in QUELIMMUNE-treated patients in

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.